Assessing Knowledge, Attitude, and Practices towards Ivermectin Pre-exposure Prophylaxis for COVID-19 among Health Care Workers

Published

2021-09-30

DOI:

https://doi.org/10.47203/IJCH.2021.v33i03.004

Keywords:

Adverse drug reaction, Ivermectin, Infection, Pandemic, SARS-CoV-2, RT-PCR, Pharmaceutical Preparations

Dimensions Badge

Issue

Section

Original Article

Authors

  • Ajay Kumar Verma King George’s Medical University, Lucknow, 226003, Uttar Pradesh
  • Anuj Kumar Pandey King George’s Medical University, Lucknow, 226003, Uttar Pradesh https://orcid.org/0000-0002-7403-9800
  • Arpita Singh Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow,226010, Uttar Pradesh
  • Jyoti Bajpai King George’s Medical University, Lucknow, 226003, Uttar Pradesh https://orcid.org/0000-0001-6337-856X
  • Surya Kant King George’s Medical University, Lucknow, 226003, Uttar Pradesh https://orcid.org/0000-0001-7520-5404
  • Darshan Kumar Bajaj King George’s Medical University, Lucknow, 226003, Uttar Pradesh

Abstract

Background: Health care workers (HCWs) are more likely to be at high risk of SARS-CoV-2 infection due to their direct and/or indirect participation in treatment facilities. Here, we aimed to evaluate the knowledge, attitude, and practices of ivermectin pre-exposure prophylaxis (PEP) in HCWs. Materials and Methods: In this observational study HCWs who were directly/indirectly involved in the medication of COVID-19 patients were selected. The study questionnaire included demographic data; knowledge, attitudes, practices, and associated adverse drug reactions (ADR) after using ivermectin as pre-exposure prophylaxis in COVID-19. Results: The mean age of the selected 306 participants was 34.41 {±standard deviation 4.08}. 66.66% of the participants were men. 15.69% of individuals had co-morbidities. HCWs were about COVID-19, and 94.12% of people know the role of ivermectin as PEP.  Additionally, 180 participants (58.82%) realized that ivermectin can cause adverse drug reactions (ADRs). 70.59% of the study-participants admitted that ivermectin has a protective effect on COVID-19, while 62.75% of the participants believed that the PEP benefits of using ivermectin outweigh the risks. 57.37% (n = 210) of HCW used ivermectin and completed the recommended medication process. Eighteen participants (8.57%) experienced adverse reactions and reported to the ADR monitoring center. Conclusion: 70.59% of the studied participants agreed that ivermectin has a protective effect on COVID-19, and 57.37% of the participants have taken ivermectin as PEP. However, 8.57% of the individuals reported ADR, but none of the participants were severe enough to discontinue the drug.

How to Cite

1.
Verma AK, Pandey AK, Singh A, Bajpai J, Kant S, Bajaj DK. Assessing Knowledge, Attitude, and Practices towards Ivermectin Pre-exposure Prophylaxis for COVID-19 among Health Care Workers. Indian J Community Health [Internet]. 2021 Sep. 30 [cited 2022 Oct. 6];33(3):430-4. Available from: https://www.iapsmupuk.org/journal/index.php/IJCH/article/view/2221

Downloads

Download data is not yet available.

References

Alam M, RM P. Ivermectin as pre-exposure prophylaxis for COVID 19 among healthcare providers in a selected tertiary hospital in Dhaka an observational study. Eur J Med Health Sci. 2020;2:1-5.

Singh A, Kumar H, Gupta P, Verma AK, Kant S, Jain A, Pandey AK, Singh SK. Assessment of knowledge, attitude, and practices towards hydroxychloroquine pre-exposure prophylaxis among health care professionals. Indian J Comm Health. 2020;32(4):681-687.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20.

The Lancet. COVID-19: protecting health-care workers. Lancet. 2020;395(10228):922.

Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020;395(10231):1225-1228.

Keeley AJ, Evans C, Colton H, Ankcorn M, Cope A, Bennett T, et al. Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS Foundation Trust in the United Kingdom, March 2020. Eurosurveillance. 2020;25(14):2000433.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787.

Vora A, Arora VK, Behera D, Tripathy S. White paper on Ivermectin as a potential therapy for COVID-19. indian journal of tuberculosis. 2020 Jul 1;67(3):448-51.

Behera P, Patro BK, Singh AK, Chandanshive PD, S. R. R, Pradhan SK, et al. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workersin India: A matched case-control study. PLoS ONE.2021. 16(2): e0247163.

Shouman W. Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19. clinicaltrials.gov Report No.: NCT04422561. Available from:https://clinicaltrials.gov/ct2/show/NCT04422561.

Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo). 2020;73(9):593-602.

Momekov G, Momekova D. Ivermectin as a potential COVID-19 treatment [26] from the pharmacokinetic point of view: Antiviral levels are not likely attainable with known dosing regimens. Biotechnology & Biotechnological Equipment. 2020;34(1);469-474.

Most read articles by the same author(s)